Prenetics Global (NASDAQ:PRENW) (NASDAQ: PRENW) is a molecular diagnostics and preventive genomics company that develops and delivers DNA-based tests and diagnostic solutions. The company’s offerings include direct-to-consumer health profiling services, clinical genetic tests, and pathogen screening assays. By combining advanced laboratory processes with digital tools, Prenetics aims to provide insights into genetic risk factors, nutrition and fitness optimization, and early disease detection.
Prenetics operates a portfolio of consumer genomics brands, including DNAFit and CircleDNA, which offer personalized reports on wellness, exercise, nutrition, and inherited health traits. In the clinical arena, the company provides tests for oncology, cardiovascular health, and pharmacogenomics to support healthcare professionals in tailoring treatments based on individual genetic profiles. During the COVID-19 pandemic, Prenetics expanded its testing capabilities to include large-scale RT-PCR and antigen screening for corporations, governments, and travel operators.
Founded in 2014 by entrepreneur Danny Yeung, Prenetics is headquartered in Hong Kong with additional laboratories and offices in Singapore, the United Kingdom, and the United States. The company serves a global customer base across Asia-Pacific, Europe, and North America, delivering test kits through online channels as well as through healthcare and corporate partnerships. Prenetics went public on the Nasdaq in late 2021 via a business combination, positioning itself to scale its product offerings and laboratory network.
Under the leadership of CEO Danny Yeung, Prenetics has secured strategic investments from life-science funds and technology investors to expand its research and development efforts. The executive team continues to pursue collaborations with hospitals, academic institutions, and employers to integrate genetic testing into preventive health programs. With an emphasis on accessibility and data security, Prenetics seeks to advance precision medicine and make genomic insights more widely available.
